
AB2 Bio gets $30M from Nippon Shinyaku for U.S. rights to Tadekinig alfa treating rare hyperinflammatory syndrome
AB2 Bio received $30 million from Nippon Shinyaku, which exercised its exclusive U.S. commercialization option for Tadekinig alfa, a treatment for Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome, a rare pediatric disease with no FDA-approve...

